Table 1.

Base case ICER results (probabilistic analysis)

Treatment	Cost (CHF)	QALY	LYa	ΔCost (CHF)	ΔQALY	ICERb (CHF/QALY gained)
Pem+Platin	74,945	1.21	1.72
Pem+Platin+Beva	173,243	1.59	2.23	98,297	0.38	Ext. dominated
Nivo+Ipi	184,060	1.78	2.45	109,115	0.57	192,585

Beva bevacizumab, CHF Swiss Francs, ext extendedly, ICER incremental cost-effectiveness ratio, ipi ipilimumab, LYs life-years, nivo nivolumab, pem pemetrexed, QALY quality-adjusted life-year

^aDiscounted

^bOf non-dominated strategies